A novel coronavirus from Wuhan in central China, named 2019-nCoV, has recently caused an epidemic of pneumonia in humans and posed a huge threat to global public health. 1 , 2 To the date 06/02/2020, 2019-nCoV has led to more than 31,0 0 0 confirmed cases and 637 deaths in China according to National Health Commission of the People's Republic of China ( http://en.nhc.gov. cn/index.html ). Cases have also been documented in a growing number of other international locations, including the United States ( https://www.cdc.gov/coronavirus/2019-ncov/index.html ). As a consequence, it is urgent to develop effective measures to control this novel coronavirus on the basis of its pathogenesis.
Host receptor recognition is a determinant for virus infection. During the time of this letter preparation, three works have just been published to explore the receptor usage of 2019-nCoV. A work by Zheng-Li Shi et al. has shown that angiotensin-converting enzyme 2 (ACE2), the receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), 3 from human, Rhinolophus sinicus bat, civet, swine but not mouse mediate 2019-nCoV infection in vitro , while the detailed mechanisms are not yet determined. 4 The other two works have reported or predicted human ACE2 usage of 2019-nCoV in a similar way to SARS-CoV mainly based on the coronavirus spike (S) glycoproteins. 5 , 6 Considering the fact that the S proteins mutate and gain capability to recognize host receptors among species, 7 , 8 there is still a lack of analyses on receptor usage of 2019-nCoV from the receptor perspective, which does not evolve as quickly as viruses.
Here, we firstly performed amino acid sequence alignment of ACE2 from different species, including human, five non-human primates (gibbon, green monkey, macaque, orangutan and chimpanzee), two companion animals (cat and dog), six domestic animals (bovine, sheep, goat, swine, horse and chicken), three wild animals (ferret, civet and Chinese horseshoe bat) and two rodents (mouse and rat). The alignment by Clustal W 2.1 shows that they share a high sequence similarity except chicken (data not shown). The result suggests that 2019-nCoV of probable bat origin may not interact with chicken ACE2 and subsequently infect them, which were not considered in the following analyses. In ACE2, the regions at position 30-41, 82-84 and 353-357 are demonstrated to be involved in the interaction with SARS-CoV S protein, where the residues at positions 31, 35, 38, 82 and 353 are critical. 9 Therefore, we took a close comparison in these regions and residues. As shown in Fig. 1 , human and non-human primates share the identity sequences in the regions and residues, implying that ACE2 from non-human primates may recognize 2019-nCoV and medi-ate its infection. As a result, non-human primates may be susceptible to 2019-nCoV and serve as animal models for antiviral research or intermediate hosts for cross-species transmission. In Fig.  1 , the residues of most companion, domestic and wild animals are conserved, especially for the critical ones stated above, while certain ones are variable. For example, Lys31, Glu35, Asp/Glu38 and Lys353 are conserved, which probably form salt bridges. Interestingly, the changes at positions 31, 38 and 82 are observed. These changes suggest steric hindrance and electrostatic interference for host-virus interaction. Taking civet ACE2 as an example, the change of Lys31 to Thr31 is likely to form a hydrogen bond instead of a salt bridge. In addition, the polar side chain of Thr82 may influence the hydrophobic interaction of the original Met82. All these changes may result in a lower binding affinity. However, an additional region covering residues 90-93 has been shown to be involved in civet ACE2 binding to SARS-CoV and enhance their interaction. 10 Consequently, we can't preclude the existence of other regions to compensate for the residue changes. With most residues in human ACE2, the ones from these compaion, domestic and wild animals may be favorable for 2019-nCoV recognition, which is in consistent with the recent work by Zheng-Li Shi et al. In case cross-species transmission, close contact with sick or asymptomatic companion, domestic and wild animals should be cautious, such as for workers in livestock farming and travellers in the wild.
In contrast, certain significant changes occur in the mouse and/or rat ACE2 compared to the human one ( Fig. 1 ) . The Asn31 and Ser82 in mouse ACE2 may not form favorable interactions with 2019-nCoV due to their electrostatic or hydrophilic characteristics. Importantly, the change into His353 in both mouse and rat ACE2 does not form a strong salt bridge as Lys353 does. Since the structural information for mouse and rat ACE2 is unavailable, we carried out homology modeling using human ACE2 (PDB code 2AJF) as template on online ( https://swissmodel.expasy.org ) for further analyses. In Fig. 2 A, the change into Ser82 in mouse ACE2 may interfere with the hydrophobic interaction of the original Met82. Additionally, the changes into Asn31 and His353 definitely affect the salt bridge formation and electrostatic potential. The change into His353 in rat ACE2 is similar in the effect on receptor-virus interaction ( Fig. 2 B) . These analyses partially explain why mouse ACE2 does not mediate 2019-nCoV infection reported by Zheng-Li Shi et al. and assume that rodents are not likely to be the susceptible host.
In conclusion, we conducted sequence and structural analyses of angiotensin-converting enzyme 2 (ACE2) from different species, which sheds some light on cross-species receptor usage of 2019-nCoV. All these analyses raise an alert on a potential interspecies transmission of 2019-nCoV and propose further surveillance in other animal populations. Structural studies on human and other species ACE2 in complex with 2019-nCoV spike protein will con- 
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Dear Editor,
Very recently, a letter in Journal of Infection reported the outbreak of the novel cornonavirus from Dec. 2019 in China, especially in Hubei province. 1 This novel cornonavirus may originate from the bat, 2 is just named as the COVID-19 by the World Health Organization (WHO). The COVID-19 outbroke from Wuhan, the capital of Hubei province, has spread to other provinces of China and even other countries. 3 Strong human-to-human transmission is established. 4 Until Feb. 11, 2020, there have been 44653 cases of COVID-19 infections confirmed in mainland China, including 1113 deaths. To prevent and control the spread of the epidemic, many strategies are needed. 5 Predicting the trend of the epidemic are quite important to the allocation of medical resources, the arrangement of production activities, and even the domestic economic development all over China. Therefore, it is very urgent to use the latest data to establish an efficient and highly suitable epidemic analysis and prediction model according to the actual situation, and then to give reliable predictions, which could provide an important refer-ence for the government to formulate emergency macroeconomic decisions and medical resources allocation.
Recently, the susceptible-exposed-infectious-recovered (SEIR) or other similar models 6, 7 are used to forecast the potential domestic and international spread of this COVID-19 epidemic with parameters estimated from other sources.The real situation could be much more complicated and changing all the time. Especially, with the implementation of the Chinese government's multiple epidemic control policies, the control of nationwide epidemic has become obvious. However, the medical supplies in Hubei will still affect the implementation of national policies. In this letter, we present the current situation of the epidemic, predict the ongoing trend with data driven analysis, and estimate the outbreak size of the COVID-19 in both Hubei and other areas in mainland China.
The data of the epidemic are listed in Table 1 and also graphically shown in Fig. 1 , in which "China" is used to denote the mainland China, and "Other" mainland China other than Hubei province. The data includes the daily confirmed(suspected) infections, totally confirmed(suspected) infections, daily deaths, and total deaths from Jan. 20, to Feb. 11, 2020, reported by the National Health Commission of the Republic of China (NHC), 8 , and Health Commission of Hubei Province (HCH). 9 Jan. 20, 2020, containing all the cases reported from 0 to 24, is the zeroth day in this letter, and then others are implied. The total number of suspected cases reaches the peak value on the 19th day (Feb. 8), and then drops rapidly. Notice that, until Feb. 11, 2020, almost all the cases of deaths (1068/1113, 96%,) locates in Hubei province, which reveals the epidemic in Hubei is much more serious than that in the other areas of China. On the hand, it states the strict quarantine and limitation on population mobility have effectively prevented outbreaks in other provinces of China.
We use function
scribe the data of daily infections and deaths in Hubei, where x = (t + 0 . 5 − t T ) with t denoting the day, and t T representing the turning point; A and k are the parameters and determined by the data together with t T . The cumulative data of infections or deaths are obtained by the integration over h ( t ). For the epidemic in the other areas of China, the data of infections shows an asymmetric character, and then will be described as s (t) = B exp −(x + k 1 e −x/k 1 ) , where x = t − t T ; the parameters B, k 1 , and k 2 together with t T , are then determined by fitting to the data. Fig. 2 shows the fit and trend predictions to the total infections and deaths in Hubei and China other than Hubei. The extracted turning point of the infections in Hubei is the 17th day, namely, Feb. 6, 2020. The epidemic in Hubei is predicted to end after Mar. 10, 2020. We estimated that the epidemic is to end up with a total of 39, 0 0 0 infections in Hubei, not including the clinically diagnosed cases since Feb. 12, which may enlarge the prediction by 1.4 times. With considered data, namely, data from Jan. 20 to Feb. 11, the average errors are bout 166 and 190 for the fits to describe the daily and cumulative infections in Hubei, respectively, corresponding to 8.6% and 1.6% for the average relative errors, respectively. Fig. 2 (b) and (e) shows the estimations of the total and daily deaths in Hubei. The predicted turning point is Feb. 12, 2020. The total deaths is estimated to be 2250. Notice the distribution of the daily deaths is delayed about 5 ∼6 days compared with the that of the daily infections. The average errors are bout 4 and 22 for the model to describe the daily and cumulative death numbers, respectively, corresponding to the relative errors 8.6% and 6.2%, respectively.
The numbers of the daily and total infections in China other than Hubei are showed in Fig. 2 (c) and 2 (f), respectively. The extracted turning point is Feb. 1, 2020 and the epidemic is expected to end on the 45th day, namely, on Mar. 5, 2020. The estimated number of cumulative infections is about 12,600 in China other Table 1 The data of epidemic caused by the COVID-19 pneumonia in the mainland China and Hubei, including (A) daily infections, (B) daily deaths, (C) total infections, (D) total deaths, (E) daily and (F) total suspected cases.
Date
China Hubei   A  B  C  D  E  F  A  B  C  D   2020/1/20  77  2  291  6  27  54  72  2  270  6  2020/1/21  149  3  440  9  26  37  105  3  375  9  2020/1/22  131  8  571  17  257  393  69  8  4 4 4  17  2020/1/23  259  8  830  25  680  1072  105  7  549  24  2020/1/24  4 4 4  16  1287  41  1118  1965  180  15  729  39  2020/1/25  688  15  1975  56  1309  2684  323  13  1052  52  2020/1/26  769  24  2744  80  3806  5794  371  24  1423  76  2020/1/27  1771  26  4515  106  2077  6973  1291  24  2714  100  2020/1/28  1459  26  5974  132  3248  9239  840  25  3554  125  2020/1/29  1737  38  7711  170 Fig. 1 (f)), we did not parameterize this data, and hence did not give a trend prediction. The COVID-19 epidemic in China is predicted to end after Mar. 20, 2020, and cause 52,0 0 0-68,0 0 0 infections and about 240 0 deaths. However, the data trends show that the quick and active strategies to reduce human exposure taken in China, such as limi-tation on population mobility and interpersonal contact rates, strict quarantine on migrants, have already had good impacts on control of the epidemic. Now the outbreak and deaths of the COVID-19 epidemic are mainly in Hubei province. After this letter has been written, the Hubei reported 14,840 confirmed infections (including 13,332 clinically diagnosed cases) on Feb. 12, 2020, which is almost 9 times greater than the data of the previous day. The huge fluctuation is due to the changing of diagnostic criteria in Hubei. And this clinical criteria taken in Hubei is expected to play an active and important role in controlling the outbreak and death rate. 
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Recently, several studies in this journal have highlighted the threat of avian influenza virus (AIV) to humans, poultry, and other animals. [1] [2] [3] [4] [5] [6] In equines, there was only one reported influenza outbreak caused by AIV, which occurred in 1989-1990 in China. However, AIV still poses a potential threat to equines.
In contrast to AIV, equine influenza virus (EIV) is a commonly known causative pathogen of acute respiratory disease in equines. To date, two subtypes of EIVs have been determined in the equine population worldwide: H7N7 and H3N8. 7 H7N7 EIV was initially identified in Prague in 1956, and the last outbreak caused by H7N7 EIV occurred in 1979. 7 H3N8 EIV was first isolated in Miami in 1963 and is currently responsible for EI outbreaks worldwide. During continuous transmission and evolution in equines, H3N8 EIV strains diverged genetically into three distinct lineages: predivergent, European, and American. 7 Historically, there have been four main EI outbreaks in mainland China, occurring in 1974 China, occurring in , 1989 China, occurring in -1990 China, occurring in , 1994 , and 20 07-20 08. In the first, third, and fourth outbreaks, the isolated EIV strains were of the H7N7 subtype, H3N8 subtype European lineage, and H3N8 subtype American lineage, respectively. In the second EI outbreak, the causative pathogen (A/equine/Jilin/1/1989) was determined to be H3N8 subtype influenza A virus (IAV) by antigenicity characterization. However, after genetic sequencing, all eight segments of A/equine/Jilin/1/1989 were genetically closer to those of avian influenza virus than those of EIV, indicating an interspecies transmission event.
The 1989-1990 EI outbreaks in China contain two major outbreaks. The first EI outbreak occurred in Jilin and Heilongjiang Provinces between March and June 1989, with a morbidity of 81% and a mortality of up to 20% in some herds. The second EI outbreak occurred in Heilongjiang Province in April 1990, with a morbidity of 41% and no mortality. The high mortality and unique antigenicity of A/equine/Jilin/1/1989 attracted the attention of EIV researchers. However, after the 1989-1990 EI outbreaks in China, the virus disappeared from the equine population for unknown reasons.
Although no evidence in the epidemiological investigation worldwide supports the continuous circulation of A/equine/Jilin/1/1989-like EIV in equines, we should not underestimate the potential of interspecies AIV transmission to equines and the possibility of future EI outbreaks caused by AIV.
The haemagglutinin (HA) of IAVs recognizes and binds the cell surface sialic acid (SA) receptor of the host respiratory tract, and then the virus enters into cells and replicates. The distribution of the SA receptor influences the host range of IAVs. Human influenza viruses preferentially bind the SAa2,6 Gal receptor, while AIVs preferentially bind the SAa2,3 Gal receptor. It has been reported that the SAa2,3 Gal receptor is abundant in the epithelial cells of the horse trachea, and animal experiments indicate that IAVs with an HA recognizing the SAa2,3 Gal receptor could replicate in horses. This finding provides a prerequisite for cross-species transmission of AIV to equines.
In fact, there were several pieces of direct molecular evidence supporting the interspecies transmission of AIV to equines, in addition to the 1989-1990 EI outbreaks in China. In 2010, Abdel-Moneim et al. reported one H5N1 EIV strain (A/equine/Egypt/ av1/2009) isolated from donkeys with cough, fever and serous nasal discharge in Egypt. 8 Sequencing results indicated that the virus had a close genetic relatedness to H5N1 AIV. In addition, H5 seroconversion was observed in 25.71% (27/105) of the examined donkeys. In 2011, He collected 284 equine lung tissue samples in China and isolated one AIV-derived H9N2 EIV strain (A/equine/Guangxi/3/2011) ( https://kns.cnki.net/ KCMS/detail/detail.aspx?dbcode=CMFD&dbname=CMFD201301& filename=1012496506.nh&v=MTMxMzc3ck5WRjI2SExleEdOVE1x WkViUElSOGVYMUx1eFlTN0RoMVQzcVRyV00xRnJDVVJMT2VaZVpt RkNua1U= ). Among the tested equine serum samples in China, 0.54% (7/1110) of samples were positive for anti-H9N2 antibody. In the 2015-2016 EI outbreaks in Pakistan, Khana et al. reported that the isolated EIV strain (A/equine/Pakistan/16) was reassorted from AIV. 9 The common characteristic for the reported cross-species transmission events of AIV to equines in China, Pakistan, and Egypt is that they occur in farming equines. 8 , 9 In the mixed farming system, equines and domestic poultry often live in close proximity. Compared with racehorses, farming equines have more opportunities to contact domestic poultry and experience long-term environmental exposure to poultry. AIV infections in poultry increase exposure risks to equines. Recently, frequent reports of cross-species transmission events of AIV to farming dogs in China and Korea also indicate the potential threat of AIV to farming animals with close contact with poultry. 10 Another problem is that the farming equines in China, Pakistan, and Egypt had no vaccination history. Even in some racehorse populations, vaccinations for EIV are not routinely performed as recommended by the World Organization for Animal Health (OIE) Expert Surveillance Panel on EI vaccine composition. Although H3N8 EIV is antigenically distinct from A/equine/Jilin/1/1989, animal experiments indicated that high doses of EI vaccines still provided complete protection against challenge with A/equine/Jilin/1/1989. Accordingly, routine vaccination with H3N8 EI vaccines in equines might prevent AIV infection to some degree, at least for H3N8 subtype AIV.
Several strategies may help reduce the threat of AIV to equines, including reducing exposure of equines to poultry, birds, and other hosts of IAV, especially animals with clinical signs of influenza virus infection; monitoring AIV prevalence in domestic poultry around equines and routinely vaccinating domestic poultry with AIV vaccines; vaccinating susceptible equines with EI vaccines, especially farming equines in close contact with domestic poultry; and monitoring the prevalence of multiple AIV subtypes in equines, not merely that of those restricted to H3N8 subtype.
None.
We read with interest recent articles in this journal regarding the utility of next-generation sequencing for the diagnosis bacterial meningitis. 1 , 2 Bacterial meningitis causes substantial morbidity and mortality worldwide. 3 Rapid identification of the microorganisms is essential for early initiation of appropriate antimicrobial therapy, thereby improving clinical outcome. Yet routine diagnostic methods fail to identify the bacteria in the majority of patients. Over the last decade, advanced sequencing technologies have greatly improved our capacity to detect the causative agents of infectious diseases in clinical samples. 4 , 5 Of these, the single molecule real-time sequencing developed by Oxford Nanopore Technologies (ONT) is a promising tool for diagnostic setting because of its short turnaround time.
In late April 2019, a 59-year old seller of fish-noodles was referred to our hospital with a 1-day history of headache, fever and vomiting. He had a history of heavy alcohol use and hepatitis C infection, and had cirrhosis and diabetes mellitus. On admission, he was unconsciousness (a Glasgow Coma Scale of 8), with a body temperature of 40 °C, a blood pressure of 140/80 mmHg and neck stiffness. Initial Gram-stain and microscopy of CSF showed Grampositive cocci, 8449 white cells/uL with 91% neutrophils, elevated protein and low glucose level, and high lactate concentration ( Fig. 1 A) . Routine bacterial culture, plus Streptococcus pneumoniae and S. suis PCRs were all negative. He was diagnosed with bacterial meningitis, and given a combination of ceftriaxone (2 g/12 h) and dexamethasone (0.4 mg/kg/12 h). His clinical condition steadily improved. His second and third CSF samples became negative by Gram stain. The other CSF parameters also improved, except the glucose, which remained low ( Fig. 1 A) . On day 20 of hospitalization, the patient suddenly became unconsciousness with fever. Brain magnetic resonance imaging showed bifrontal abscesses ( Fig. 1 B) . After consulting a local neurosurgeon, aspiration of the brain abscesses was not advised and the patient was treated empirically with meropenem (2 g/8 h) and vancomycin (1 g/8 h). Due to continued diagnostic uncertainty, we performed 16S rRNA sequencing of the admission CSF, stored as part of an going clinical study (Supplementary Materials), using an established Sangersequencing based 16S rRNA method. 6 Subsequently, analysis of the obtained sequences revealed evidence of S. agalactiae (Supplementary Figure 1 ). Given this new diagnostic result of the admission CSF and because the patient had recovered clinically, the patient was given 24 million units of penicillin G for every 4 h. After day 43 of hospitalization, all CSF parameters had normalised ( Fig. 1 A) . Likewise, on CT scan the brain abscess was now significantly improved ( Fig. 1 C) . The patient was discharged with full clinical recovery.
Additionally, MinION sequencing of complete 16S rRNA gene was retrospectively carried out on the extracted nucleic acid of the admission CSF yielded a total of 14,848 reads after 100 min of sequencing run. Of these, 11,556 reads (79%) were successfully aligned to S. agalactiae ( Fig. 1 D) . The remaining reads were assigned to other Streptococcus species (mostly S. dysgalacticiae ( n = 2.145, 14%)), likely attributed to a combination of the high level of sequence similarities of the 16S rRNA region between them and the sequencing errors introduced by the MinION systems. Analysis of sequencing data generated during the 25, 50 and 75 min of sequencing run time also yielded the same results (Supplementary Figure 2 ). Details about the MinION procedure are presented in Supplementary Materials.
To further assess of the utility of CSF MinION sequencing of 16S rRNA gene for the detection of bacterial meningitis pathogens, six CSF samples from patients with confirmed bacterial meningitis enrolled in the abovementioned clinical study were tested ( Table  1 ) . Analysis of the MinION reads obtained after two hours of the sequencing run showed that the majority of reads were correctly assigned to the corresponding bacterial species ( S. pneumoniae and S. suis) or genus ( Neisseria ) found in the CSF samples by diagnostic work up of the clinical study ( Fig. 1 E and Table 1 ). Additional analysis of the obtained reads generated at two earlier time points (20 min and 60 min) of the sequencing run generated the same results ( Table 1 ) .
Collectively, we report the first application of MinION sequencing of 16S rRNA gene to detect bacterial meningitis causing pathogens in CSF samples from a low and middle-income country. The assay was able to detect the bacterial causes in all of the seven tested CSF samples. Meanwhile, Gram stain and culture, the two most commonly used methods in clinical microbiology laboratories worldwide, were negative in 3/7 samples. ( Fig. 1 and Table 1 ).
In addition to CSF samples described in the present study and a recent pilot study from Korea, 7 successful detections of Haemophilus influenzae in sputum and Campylobacter fetus in culture materials by MinION sequencing of 16S rRNA have recently been reported. 8 Together, the data suggest that MinION sequencing of 16S rRNA is a sensitive method for rapid and accurate detection of pan-bacterial pathogens, including unexpected microorganisms, in clinical samples. Additionally, the bacterial species information generated by the analysis of 16S rRNA sequences can be useful for disease surveillance and vaccine evaluation. Thus, the application of the method would be relevant for both patient management and epidemiological research. Indeed, to the best of our knowledge the present study represents the first report of S. agalactiae associated meningitis in Vietnam. Because the incidence of invasive diseases (including meningitis) caused by S. agalactiae has been reported with increased frequency in recent years, 9 S. agalactiae should be considered as an important differential diagnosis for patients presenting with acute CNS infections in Vietnam.
Owing to the unavailability of the reagents at the time of patient admission, we were not able to perform real-time diagnosis using MinION sequencing on the collected CSF samples. However, same day diagnosis is theoretically achievable, because the current workflow takes 5 -6 h to operate. Prospective study is urgently needed to assess its translational potential in the diagnosis of bacterial meningitis.
The clinical study
Since September 2017, a prospective observational study aiming at exploring the utility potential of next-generation sequencing in patients presenting with central nervous system (CNS) infections has been conducted in the brain infection ward of the Hospital for Tropical Diseases (HTD) in Ho Chi Minh City, Vietnam. HTD is a tertiary referral hospital for patients with infectious diseases from southern provinces of Vietnam, serving a population of > 40 million. Any patient ( ≥16 years) with an indication for lumbar puncture was eligible for enrolment. Patient was excluded if no written informed consent was obtained. As per the study protocol, CSF, plasma and urine samples were collected at presentation alongside demographic, meta-clinical data and results of routine diagnosis. After collection, all clinical specimens were stored at −80 °C until analysis.
The clinical study received approvals from the Institutional Review Board of the HTD and the Oxford Tropical Research Ethics Committee of the University of Oxford. Written informed consent was obtained from each study participant or relative (if the patient was unconsciousness).
MinION sequencing of 16S rRNA
Sequencing of complete 16S rRNA gene was retrospectively performed using MinION Nanopore sequencer (ONT), following the manufacturer's instructions. In brief, amplification of the complete 16S rRNA gene and library preparation were carried out on extracted nucleic acid using 16S Barcoding Kit (SQK-RAB204, ONT) and primers (27F 5 -AGAGTTTGATCCTGGCTCAG-3 and 1492R 5 -GGTTACCTTGTTACGACTT-3 ), followed by the sequencing of the amplified product using R9.4 Flow cells (ONT). MinION reads were first basecalled using Albacore v2.1.7 (ONT), followed by demultiplexing using Porechop ( https://github.com/rrwick/Porechop ). Determination of bacterial genus/species composition in the obtained reads was then carried out using Epi2Me interface (Metrichor, Oxford, UK), a platform for cloud-based analysis of MinION data. Overall, the whole procedure of MinION sequencing of 16S rRNA gene takes 5-6 h to complete ( Supplementary Figure 3) . 
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Several aspects of influenza have been highlighted recently, including its global, comparative seasonality, 1 and issues around rapid point-of-care testing. 2 In addition, the UK has a national surveillance programme, the UK Severe Influenza Surveillance System (USISS) to monitor and investigate severe cases of influenza across the country, 3 including severe cases of influenza admitted to intensive care (ICU) and high dependency units (HDU). 4 Specifically, the aim of this latter arm was to "monitor and estimate the impact of seasonal influenza on the population" and to "describe the epidemiology of severe disease." This surveillance began in the 2011-2012 influenza season and has continued to the present, with mandatory participation by all NHS Trusts.
Leicester is one of 5 NHS commissioned centres in the UK providing extra-corporeal membrane oxygenation (ECMO) support for severe acute respiratory failure in adults. This process involves draining deoxygenated venous blood from the superior and inferior vena cavae, pumping this blood through a membrane lung, where oxygenation and carbon dioxide elimination take place. Oxygenated blood is delivered back into the right atrium, therefore replacing the function of the native lung. In this way, ECMO can be used to support patients with respiratory failure of any cause. Acceptance for admission for ECMO support follows referral to the ECMO service via structured questionnaire and discussion with the ECMO consultant on-call. Patients are commenced on ECMO where benefits are deemed to outweigh the risks in patients with potentially reversible respiratory failure, who are already on maximal conventional therapy at their referring centre, and who are not achieving lung protective ventilation. 5 Here, as part of our national USISS role, we describe severe influenza cases that required ECMO support in whom the predominant indications were severe hypoxia with a PaO 2 :FiO 2 ratio of < 100 despite maximal conventional therapy, and/or hypercapnoeic respiratory failure with a pH < 7.2 despite ventilation pressures > 30 cm H 2 O.
During the 2018-2019 influenza season 33 cases of severe influenza were admitted to Glenfield Hospital for ECMO from our referring centres. Most were male (23/33, 69.7%, 28-62 years, BMI: 17-47; female 10/33, 27-51 years, BMI: 21-38), and of white British ethnicity (30/33, 91.0%; with 1 each of Chinese, Asian, African ethnicity). Comorbidities included, obesity, hypertension, asthma, COPD, diabetes, anxiety, depression, epilepsy, a history of smoking and alcohol use (or abuse). All cases except for one influenza A(H3N2) infection (possibly two as subtyping was not performed for another sample) were due to influenza A(H1N1)pdm09. Only one case had a history of influenza vaccination. Various 'on referral' ECMO-related parameters were extracted, as well as contemporaneous laboratory results. These were statistically compared between patients who died ( n = 8) and those who survived using t -test or Mann-Whitney test for continuous variables and Fisherexact test for categorical variables. Correlation between duration on ECMO and laboratory parameters was assessed using Spearman's rank correlation coefficient. ( n = 24) ( Tables 1 and 2 ) .
Surprisingly, it was found that on direct comparison, most of the referral parameters for patients starting ECMO were not statistically different between those influenza-infected patients that eventually survived ( n = 24) versus those who died ( n = 8) -a case fatality rate of 25%. One patient was dropped from this analysis due to some missing data.
Only the respiratory rate (RR, p = 0.041) and the lactate ( p = 0.008) showed statistically significant differences between the two groups, with higher values being found in the patients who ECMO -extra-corporeal membrane oxygenation; SOFA -sequential organ failure assessment; PEEP -positive end expiratory pressure; H 2 O -water; bpm -breaths per minute; PaO 2 /PaCO 2 -partial pressure of arterial oxygen/carbon dioxide; ALTalanine aminotransferase. * Rank correlation coefficient measures the strength and direction of a relationship between two variables. The coefficient ranges from −1 to 1 with 1 indicating a strong positive relationship between two variables and −1 indicating a strong negative relationship. A correlation coefficient close to 0 means the relationship between the two variables is very weak.
died ( Table 1 ) . However, clinically, these differences are of doubtful significance, as the RR is at the discretion of the parent clinical team prior to referral to ECMO, and the lactate levels are normal in the survivors and only marginally elevated in those who died which will again be dependent on use of CVVH. The higher PaO 2 :FiO 2 (P:F) ratio was statistically significantly correlated ( p = 0.020) with a shorter duration of ECMO, which suggests those with less severe disease recover quicker ( Table 2 ) .
Many studies have reported on intensive care patient outcomes of the 2009 influenza A(H1N1)pdm09 pandemic, with or without the use of ECMO. In one study from Australia, where ECMO was used, of 68 patients with confirmed influenza A (53 A(H1N1)pdm09, 8 un-subtyped) infection, 14 (21%) had died mainly due to intracranial and other forms of haemorrhage ( n = 10), or intractable respiratory failure ( n = 4). 6 Another study from the USA, where influenza A(H1N1)pdm09-infected patients had non-ECMO ICU admission, of 154 cases, 48 (37%) developed acute respiratory distress syndrome (ARDS), of whom 37 (24%) died. 7 A more recent study from Spain that reviewed influenza A(H1N1)pdm09 cases admitted to ICU (non-ECMO) from 2009-2015, found that of a total of 2421 cases, the mortality ranged from 18.8% (for community-acquired influenza) to 32.9% (for hospitalacquired influenza). 8 These ECMO-ICU case fatality rates of severe influenza A(H1N1)pdm09 infection are similar to ours of 25% reported here, though compared to the specific ECMO patient cohort, 6 the causes of death in our patients were more variable, including intracranial and other haemorrhage ( n = 3), sepsis and multi-organ failure ( n = 2), respiratory failure ( n = 1), post-cardiopulmonary resuscitation hypoxic brain injury ( n = 1), and ischaemic bowel associated with atrial fibrillation ( n = 1).
Thus, even after 10 years of experience with this 'new' pandemic influenza A(H1N1)pdm09 virus, across almost the entire adult age-range ( ∼25-70 years in these previous studies), [6] [7] [8] it appears that for severe cases, globally, the survival of such patients appears not to have improved. This may be somewhat surprising as the world's populations have become more immunologically experienced with this virus, which is now considered as a seasonal influenza virus that should be conferring some degree of persisting, cross-reactive individual and herd immunity over consecutive seasons. 9 This may be due to some predisposing genetic or environmental factors in individual patients, which should reinforce the general message that seasonal influenza immunisation is still recommended to minimise the number of people needing ICU or ECMO support for severe influenza infection.
More detailed monitoring on how these physiological parameters change over time (perhaps including more complex cytokine studies), in these severely ill, influenza A(H1N1)pdm09-infected patients admitted to ICU-ECMO units, may eventually yield data to improve their management and clinical outcomes.
Assessment of serum CD5L as a biomarker to distinguish etiology and predict mortality in adults with pneumonia

Dear Editor,
We read with interest the report by Stalenhoef and colleagues in this journal who show that biomarker guided triage can reduce hospitalization rate in community acquired febrile urinary tract infection (REF). 1 Here we report on a prospective observational analysis of the biomarker: CD5 antigen like protein (CD5L), in serum samples collected from 64 patients diagnosed with pneumonia 2 and 44 healthy adults between 2018 and 2019.
The demographic and clinical characteristics of the 64 adults (males 70.3%; mean age 66 ± 20 years) with pneumonia were summarized in Table 1 . 57 (89.1%) bacterial pneumonia patients (including 34 patients with confirmed bacterial pneumonia 2 and 23 patients with suspected bacterial pneumonia 3 ) and 7(10.9%) viral pneumonia patients were studied. There were significant differences in age, sex, WBC, NEU%, CRP, PCT, CD5L, APACHE II scores and length of ICU stay between bacterial pneumonia and viral pneumonia. The pathogens responsible for pneumonia were described in Supplementary Table 1 . Globally, Gram-negative bacteria infection is more common than Gram-positive bacteria infection in pneumonia. Among them, Acinetobacter baumannii (16, 59.3%) was considered the major pathogen in gram-negative bacteria and Staphylococcus aureus (3, 42.9%) was considered the major pathogen in Gram-positive bacteria. In viral pneumonia, influenza A (H1N1) was detected as the unique pathogen.
In the study of the diagnostic performance of serum CD5L to identify etiology of pneumonia, as we found in Supplementary  Fig. 1 , no matter in total bacterial pneumonia, suspected bacterial pneumonia or confirmed bacterial pneumonia, the serum of CD5L levels on day of pneumonia diagnosis were significantly higher than those in viral pneumonia and healthy control subjects. For evaluating the diagnostic performance of CD5L to differentiate bacterial from viral infection in pneumonia, ROC analysis was conducted for the above bacterial pneumonia ( Supplementary Fig. 2 ) and compared with routine laboratory markers ( Table 2 ). By horizontal comparison, we found that the best AUC was for CD5L (AUC = 0.89), better than NEU% (AUC = 0.79), WBC (AUC = 0.79), CRP (AUC = 0.78) and even PCT (AUC = 0.85). Interestingly, by longitudinal comparison, the AUC was observed highest in confirmed bacterial pneumonia (AUC = 0.92), intermediate in all bacterial pneumonia (AUC = 0.89), and lowest in suspected bacterial pneumonia (AUC = 0.84), which may better elucidate the diagnostic performance of CD5L for etiology diagnosis in pneumonia patients. Although there are 23 patients with suspected bacterial pneumonia for which no definitive pathogen was found, our result here may still provide a new treatment for bacterial infection identification in pneumonia patients for the current limitations in direct pathogen testing make it difficult to identify the pathogen at the time of diagnosis 4 . Besides, as a potential biomarker to distinguish pathogens [5] [6] [7] [8] , CD5L levels were also significantly correlated with WBC, NEU%, CRP and PCT ( Supplementary Fig. 3 ) in patients with pneumonia.
In the study of the diagnostic performance of serum CD5L to predict mortality in adults with pneumonia, mortality was defined as death occurring within 30 days after the onset of pneumonia. As we observed in Supplementary Fig. 4A , serum CD5L levels on day of pneumonia diagnosis were significantly higher in non-survivors ( n = 18) than survivors ( n = 46) ( p < 0.001). To ensure that serum CD5L levels were not influenced by the class of the infection in the specimens, Spearman's rank correlation analysis was performed between serum CD5L levels and poor prognosis related scores 9 , 10 (SOFA and APACHE II scores) in patients with total bacterial pneumonia, suspected bacterial pneumonia, confirmed bacterial pneumonia and viral pneumonia, respectively. Our correlation analysis between serum CD5L levels and SOFA or APACHE II scores shows that no matter for bacterial pneumonia or viral pneumonia, the CD5L levels showed positive correlation with SOFA and APACHE II scores ( Supplementary Figs. 5 and 6 ). Furthermore, the AUC of CD5L for identifying 30-day mortality in adult pneumonia patients was 0.79 ( Supplementary Fig. 4B ), a value means good diagnostic performance, which is consistent with Gao's study 9 before.
Therefore, we found that determining serum CD5L concentrations on day of pneumonia diagnosis was of great value in identifying bacterial infection from viral infection and predicting 30day mortality in adult patients with pneumonia, which suggests that CD5L may work for the etiologic diagnosis and could represent a novel biomarker for identification of a group of patients with pneumonia presenting with higher risk of death. These findings encourage further effort s aimed at exploring the clinical value of circulating CD5L to help early clinical decision-making in human pneumonia. 
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None. high morbidity and mortality (up to 100%). ASF is a devastating threat to pig agriculture and is responsible for serious production and economic losses. The ASFV genome is 170-193 kilo base pairs in length 2 and has been divided into 24 different genotypes based on their B646L gene sequence, a gene which encodes the capsid protein p72. 3 , 4 Our previous study showed that the p72 gene located in a very low genetic diversity region of the genome. 5 Ye and colleagues, however, identified two novel genotypes XXV and XXVI, with genotype XXVI being especially divergent from all other genotypes. 1 To examine this unexpected result, in this study, we reanalyzed their data to evaluate the reliability of these two genotypes. We collected 716 available p72 gene sequences from NCBI ( http://www.ncbi.nlm.nih.gov/ ), which we then aligned with MAFFT software, a fast multiple sequence alignment program. 6 The alignments show that genotype XXV (accession number FR668409) has a single amino acid change at position 506 compared to genotype I, while for genotype XXVI (accession numbers FR668404 and FR668418), the region coding for amino acid residues 509 to 528 differs greatly compared to all other genotypes ( Fig. 1 A) . To examine this in greater detail, we calculated genetic distance across the p72 coding sequence in 60 bp sliding windows, with a step size of 10 bp, between these two sequences and the 24 other genotypes ( Fig. 1 B) . This sliding window analysis shows these two sequences for genotype XXVI have a region that is very divergent, with genetic distance up to 0.5067 from the other genotypes, while the genetic distances of the remaining regions are less than 0.1 ( Fig. 1 B) .
Genetic distances for ASFVs were calculated for 182 coding gene sequences, from 42 available complete genomes of ASFVs, to assess the overall divergence. Pairwise genetic distances of each gene for all ASFV strains were calculated. The mean pairwise genetic distance for ASFV genes was 0.041 ( Fig. 2 ) , which is much lower than this divergent region of these two sequences for genotype XXVI (0.5067). Therefore, it seems highly unlikely that a gene has such a highly divergent region.
Since recombination frequently occurs in ASFVs, 5 we conducted a recombination analysis with the RDP4 program, which used the 3seq, bootscan, chimaera, genecov, lard, maxchi, rdp and siscan detection methods, 7 to determine whether recombination might have occurred in the XXVI genotype. We found reliable evidence for recombination events in both p72 genotype XXVI sequences ( Fig. 1 C) . This suggests that the very highly divergent region of this p72 genotype is not homologous with other p72 genotypes. We used Blastn, from NCBI ( https://blast.ncbi.nlm.nih.gov/Blast.cgi ), to identify a source for this highly divergent region, however, no similarity sequence was found.
We then mapped the multiple amino acid changes found in genotype XXVI to the 3D structure of p72 ( Fig. 3 ) . The changed sites (marked in red in Fig. 3 ) are located in the Dec loop, a region which plays an important role in the formation of the trimer spike. 8 The amino acid mutations result in changes of electrostatic potential, hydrophobicity, and steric hindrance. It seems unlikely to have so many changes in such a functionally important region.
In our previous studies we noticed that sequences directly submitted by individual laboratories to GenBank often contain errors such as misidentification of species, sampling error, contamination, or are pseudogenes, which can lead to sequence analysis problems and erroneous conclusions. 9 , 10 Sequences that deviate from the overall intraspecific pairwise divergence are potentially erroneous. 9 , 10 Since genotype XXVI deviates from other genotypes not only in genetic distance, but also in protein structure, and mutations occur in the flanking regions of the sequences, we deduced that these reported mutations might be due to low quality sequencing. We identified the original manuscript reporting the three sequences of genotypes XXV and XXVI, 11 where the authors stated that the "Alignment and translation of sequences obtained from Sardinian isolates revealed that the C-terminal end of p72 gene was completely conserved between the sequences compared". This statement indicates that these sequences did not considerably diverge from previously reported ASFV p72 sequences, and thus, suggests that an error in these sequences had been introduced upon submitting them to GenBank. Further examination of the original samples and sequences is needed. We contacted the corresponding author of this manuscript to check these three sequences, and were told that these three p72 sequences were all genotype I, and had some errors when submitted to GenBank.
In conclusion, the two novel genotypes of ASFVs (XXV and XXVI) identified by Ye and colleagues 1 are misled by problematic sequences. As reminded by our previous studies, many problematic sequences are present in GenBank, which can lead to problems in downstream analyses. 9 , 10 Thus, when published data is used for new analyses, the first set in the process of data analyses should be to filter these sequences for potential errors to reduce the possibility of reaching incorrect conclusions. If conclusions are based on obviously strange sequences, then we should trace back the data to their original source, and manuscript, and contact the corresponding authors before making conclusions based on these sequences.
Recent correspondence in this Journal has highlighted that accurate determination of Hepatitis C Virus (HCV) genotype/subtype can be critical; as this may impact response to direct-acting antiviral (DAA) therapies. 1 Chronic HCV infection is a major cause of cirrhosis and hepatocellular carcinoma. It was reported that approximate 71 million people worldwide had chronic HCV infection with about 1.75 million new HCV infections and about 399,0 0 0 deaths per year. 2 Currently, DAA treatment regimens that target NS3/NS4A protease, NS5A phosphor-protein and the NS5B polymerase have shown high safe and high rates of sustained virologic response in HCV chronically infected patients ( > 90%). 3 However, under selective pressure from these drugs, drug resistance-associated substitutions (RAS) can emerge during this therapy and result in treatment failure in 2 −10% of patients. 4 Therefore, HCV infection is still a major global health concern.
To date, eight confirmed genotypes have been characterized based on > 30% sequence divergence in the complete HCV genome, and genotypes are further classified into > 80 subtypes with a sequence divergence of > 15% to other subtypes of the same geno-type. 5 In the current study, we characterized a new HCV subtypes among chronic hepatitis C patients in Yunnan, China, initially designated as 6xi, further analyzed its evolutionary history and investigated its baseline RAS by next generation sequencing (NGS) method.
Plasma samples were collected between January 2018 and October 2018 from 160 chronic hepatitis C patients from Kunming city in Yunnan, China (Fig. S1A) . The samples met the following inclusion criteria: (1) hepatitis C antibody-positive for 6 months with normal serum alanine aminotransferase (ALT) levels; (2) subject was residing in Yunnan province and was over 18 years old; (3) complete demographic information and clinical data were available; (4) consented to the use of patient information in studies on HCV epidemics; and (5) were treatment-naïve during sampling. There was no epidemiologic link among these individuals. The study was approved by the First People's Hospital of Yunnan Province Ethics Committee. Written informed consent was obtained from all participants prior to the study.
Out of a total of 160 chronic hepatitis C patients, 152 partial NS5B gene fragments were successfully amplified and sequenced with a success rate of 95.0% (152/160). Multiple subtypes were identified in 152 subjects, including subtype 3b (36.2%, 55/152), 3a (23.7%, 36/152), 1b (19.1%, 29/152), 2a (8.5%, 13/152), 6n (7.9%, 12/152), 6a (2.0%, 3/152), and 1a (1.3%, 2/152) ( Fig. S1B ). Interestingly, the remaining two strains (1.3%, 2/152) involving YNKH261 and YNKH284 together with the isolate KM35 reported formed a novel separate cluster in the genotype 6 with an 82% bootstrap value, indicating a potential new HCV subtype 6.
To confirm that the two strains belong to a novel HCV subtype 6, their complete genome sequences were successfully amplified and sequenced with 12 overlapping fragments. Further, phylogenetic analysis was performed along with HCV reference sequences of representative subtypes 6a-6xh. The result showed that the two strains and isolate KM35 formed a distinct monophyletic cluster supported by a high bootstrap value of 100%. The three strains were isolated from three HIV-1 infected patients without obvious epidemiological linkage in Yunnan and showed no evidence of recombination using Bootscan analysis ( Fig. 1 (B) ). Moreover, the intergroup nucleotide divergence (mean ± SD) % over the fulllength genome sequences of the isolates (YNKH261, YNKH284, and KM35) were compared to that of representative subtypes (6a-6xh) ( Fig. 1 (C) ). The results revealed that the three strains were different from known HCV subtypes of 6a-6xh by 16.5-28.5%. Therefore, the three strains are initially designated 6xi.
To better understand the time of emergence of HCV 6xi, we performed bayesian molecular clock analyses using full-length genome sequences to estimate the time to the most recent common ancestor (tMRCA). As shown in Fig. 2 (A) , the estimated tMR-CAs for the genotype 6xi was 1971.1 [95% highest probability density (HPD): 1951. 1, 1991.4 ]. In addition, to further investigate baseline RAS of subtype 6xi, naturally occurring resistance-associated substitutions (RAS) were analyzed for the NS3, NS5A and NS5B sequences using next generation sequencing (NGS) method. Strikingly, HCV 6xi strains contain the substitution 28 V with a 100% frequency of mutations in the NS5A protein contributing to resistance to Velpatasvir of NS5A phosphoprotein inhibitor, 6 suggesting that the subtype 6xi maybe basically resistant to NS5A inhibitors ( Fig. 2 (B) ).
Among the HCV eight genotypes, genotype 6 exhibits a high degree of genetic complexity and diversity, and 31 subtypes have been confirmed by the International Committee on Taxonomy of Viruses. 7 In China, HCV genotype 6 is common, and subtype 6a is the most prevalent subtype, primarily distributed in Guangdong, 6n is the second most prevalent subtype, mainly found in Yunnan, followed by subtypes 6xa, 6 g, 6v, 6 w, 6e, 6b, 6j, 6q,and 6r among genotype 6 isolates. 8 -10 To our knowledge, 6xi is the eighth detection of novel HCV subtypes 6 in China combined with previously identified 6a, 6e, 6n, 6v, 6xa, 6xe and 6xh, resulting in genotype 6 to expand to 32 subtypes in the world. Our findings again demonstrated that HCV genotype 6 was more complex and diverse.
In summary, we characterized a new HCV subtype 6xi based on the characteristics of a monophyletic cluster, > 15% genetic distances, no significant evidence of recombination, and no epidemiologic link among individuals. In addition, bayesian analyses showed that 6xi may originate around the year 1971, and the strains of HCV 6xi naturally contain the substitution 28 V in the NS5A protein contributing to resistance to Velpatasvir of NS5A phosphoprotein inhibitor. The present finding again highlights the genetic characteristics and HCV strains in Yunnan, and the urgent need for continuous molecular screening and epidemic surveillance in Yunnan to implement effective measures to reduce HCV transmission.
The authors declare no competing financial interests.
High risk of hepatitis B virus reactivation among patients treated with direct-acting antivirals and coinfected with HCV and HIV
We recently read the article by Corma-Gómez A. et al. on which the authors described a higher probability of relapses with sofosbuvir/ledipasvir 8 weeks compared with 12 weeks of HCV (hepatitis C virus) among HIV (human immunodeficiency virus)/HCV coinfected patients. 1 In this regard, coinfections of HIV/ HCV also with hepatitis B virus (HBV) is associated with high mortality and comorbidity too. The persistence of HBV DNA within the core cell in the absence of HBsAg and even after clearance of the infection has been described previously in immunosuppressed patients, where HBV screening and prophylaxis is recommended. 2 Interestingly, HBV reactivation has recently emerged during or after HCV treatment with direct-acting antivirals (DAA). [3] [4] [5] The US Food and Drug Administration issued a warning about this risk in 2016, 6 until that moment 24 cases were reported, two of which died. Although specific mechanisms of this event are not well known, it has been suggested that HCV core proteins could inhibit HBV replication and HBsAg production as well as production of envelope proteins, being HBcAb the only marker of the presence of HBV. 2 In this context, treatment with DAA would produce a drastic and rapidly blocking of HCV replication providing the opportunity to HBV to emerge and produce an immune reconstitution syndrome.
The interference HBV-HCV has been outlined in 24% of patients with chronic HBV infection (HBsAg-positive serology) and 1.4% of patients with resolved HBV infections (HBsAg-negative and HBcAbpositive) in a recently published systematic review and metaanalysis of patients with HCV-HBV. 7 In most cases, these reports have focused on coinfection HCV-HBV, but there is still a concern about patients triple-infected with HCV, HBV and HIV.
Although most cases reported occur in HBsAg-positive, the main concern affects to patients with a basal serology showing HBcAb-positive, HBsAg-negative and HBsAb-negative. HBsAgpositive was associated with higher rates of HBV reactivations compared with HBsAg-negative and HBcAb-positive patients. 8 There is no clear information about this issue in HBsAg-negative, HBcAb-positive, and, when occurs, it is considered an uncommon event. 9 Reactivation of HBV is characterized by reappearance or increase in HBV DNA levels, and could also be accompanied by symptoms of hepatitis. The cases reported previously did show difference in the time of presentation of clinical symptoms, they used to start either during or after DAA treatment. It seems that HBV reactivation usually occurs early after DAA initiation treatment (4-8 weeks) while otherwise can occur after treatment completion. In that way, it seems necessary that HBV infection should be monitored early after DAA initiation.
The most recent European Association for the Study of the Liver (EASL) guideline about HBV infection, recommends that patients HBsAg-negative and HBcAb-positive undergoing DAA treatment should be monitored and tested for HBV reactivation only in case of ALT elevation. 10 They also recommend performing HBV DNA levels only in case of ALT increase. At the same time, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Disease Society of America (IDSA) guideline has been recently updated recommendations to monitor HBV DNA levels only in patients HBsAg-positive, but they emphasize that there is not enough data to monitoring DNA among patients HBcAbpositive or HBcAb-positive and HBsAb-positive. They remark that a reactivation should be considered if an unexplained increase in liver enzyme is present. In HIV patients, they provide the same recommendations. 11 In a recent review of the literature, the authors also recommend to perform an HBV DNA only in patients with altered ALT. 9 A meta-analysis recommended not to perform an HBV DNA test in this case due to low rate of incidence and the associated cost which needs to be considered especially in an endemic HBV areas. 7 Few data exist in HIV patients. The fact that many triple-infected patients are receiving antiretroviral therapy including (ART) nucleoside/nucleotide analogous, as tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF), both active against HBV, suggest that HBV reactivation rate could be underestimated. In a recently published review, Chang et al., recommend to perform an HBV DNA test at baseline in triple-infected patients. If positive, an HBV-active antiretroviral therapy (ART) should be started and HBV DNA needs to be monitored every 4 weeks during treatment and until week 12 after completion of treatment. However, if baseline HBV DNA is negative they match with AASLD/IDSA and EASL recommendations. 12 One of our patients has a basal serology with HBcAb-IgGpositive, both HBsAg-and HBsAb-negatives, and undetectable HBV DNA levels, prior to treatment with DAAs. Regarding HIV infection, he has an analogues-free regimen. One month after having finished treatment with DAAs, the patient consulted because of abdominal pain, nausea and jaundice. He had a total bilirubin level of 11 mg/dl, AST 1025 IU/l, ALT 642 IU/l and INR 1.30. A HBV viral load of 6,193,455 IU/mL was detected; HBsAg, HBcAb-IgM and HBeAg were positive. There were no reasons to believe that he was re-infected. Treatment with entecavir was initiated; however, the clinical evolution was unfavorable and died as a result of an acute liver failure. The HBV viral load was requested from the stored samples drawn during the treatment of HCV showing that HBV viral load was undetectable at the beginning of treatment and in week 2, but progressively increased to 98 IU/mL in week 8 and up to 82,700 IU/mL in week 4 after treatment completion. During the follow-up of DAA treatment ALT and AST remained normal. This case changed our daily practice, since then all HIV patients and more specifically those not treated with either TDF or TAF and presenting a previous HBcAb-positive, are followed using DNA levels and not only monitoring hepatic enzymes, as recommended by guidelines. We consider that this case may reflect the necessity of change the current guidelines. We recommend to perform a periodic monitoring of HBV reactivation using HBV DNA during and after DAA therapy in HBsAg-negative and HBcAb-positive patients, independently of HBsAb presence, hepatic enzymes and clinical symptoms, particularly in HIV patients who are not receiving active treatment of HBV.
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The heterogeneity of influenza seasonality by subtype and lineage in China
Dear Editor,
Recently, a notable pattern of synchrony of influenza A and B virus, and respiratory syncytial virus incidence peaks globally was reported in this journal. 1 A previous study characterized seasonal pattern of influenza A and B in China and identified three epidemiological regions featured by distinct seasonality. 2 On the basis of laboratory surveillance data from 30 Chinese provinces spanning about 12 years from October 2004 through January 2017, our study further characterized seasonal patterns of circulating influenza A subtypes and influenza B lineages in the three defined epidemiological regions. Our study revealed that pre-2009 A(H1N1) and A(H3N2) displayed wintertime and summertime epidemics in midlatitude and southernmost Chinese provinces with subtropical climate, wavelet analysis demonstrated the two subtypes displayed twice-annual cycle in some years in mid-latitude Chinese provinces ( Fig. 1 (a)-(h) ). However, the two subtypes peaks in the winter with annual or longer cycle in northern Chinese provinces. Influenza A(H1N1)pdm09 B/Victoria and B/Yamagata virus all displayed epidemics in the winter or winter-spring with annual or longer cycle in all three epidemiological regions.
We developed univariate and multivariate regression models to evaluate the association between climatic factors and the presence or absence of epidemics of each influenza subtype and lineage (positive proportion ≥5%) in the southernmost provinces where heating system is not generally used in the winter so temperature and relative humidity in external conditions in winter are close to those in indoor environment where people spend most of the time. We fitted the mixed-effects logistic regression model to control for the repeated measurements in each province of the region cluster. We kept one of temperature and absolute humidity (representative of vapor pressure) with smaller Akaike information criterion in the model to reduce of multi-collinearity due to a high degree of correlation between the two factors.
Our analysis indicated temperature, humidity and rainfall were environmental predictors of influenza subtype/lineage-specific epidemics in the southernmost provinces when a 1-week lag of influenza epidemics behind climate was considered, which was similar to the findings from some ecological studies ( Table 1 ). 3 Our study indicated the U-shaped relationship between absolute humidity (AH) and pre-2009 A(H1N1) or A(H3N2) epidemics in the southernmost provinces, and suggest that high levels of AH in the summer, and low levels of AH in the winter increased the possibility of epidemics of the two subtypes. 3 In our analysis, lower temperature was an environmental driver of A (H1N1)pdm09 and B/Yamagata epidemics in the southernmost provinces while there were bimodal associations between temperature, rainfall and B/Victoria epidemics with highest probability of B/Victoria epidemics at 11.7 °C of daily average temperature and 11.3 mm of daily average rainfall.
Although seasonal changes in human behaviors, such as school attendance or crowding indoors, and seasonal variations in immunity, such as melatonin and vitamin D levels have been proposed to account for the seasonal nature of influenza, 4 our findings suggest that the heterogeneity in influenza subtype/lineage-specific seasonality patterns could be driven by seasonal variations in virus survival, transmission and adaptive immunity by influenza subtype and lineage because of the same behavior modes and background of non-adaptive immunity in the same regions and seasons. We propose a hypothesis: under humid and hot condition the dominant transmission mode(s) for A(H1N1)pdm09, B/Victoria and B/Yamagata might have reduced efficiency, however, there could be effective transmission mode(s) for A(H3N2) and pre-2009 A(H1N1) virus.
Some experimental studies were performed to establishing a causal link between humidity, temperature and influenza virus survival/transmission. 5 Transmission of influenza A (H3N2), A(H1N1)pdm09, B/Victoria and B/Yamagata virus by respiratory droplets or aerosols in the guinea pig model proceeds most readily under cold, dry conditions. 5 Low humidity and temperature increased the stability of influenza virus in aerosols and on surfaces. Furthermore, aerosol transmission of A (H3N2) virus in the guinea pig model was almost completely blocked at 30 °C, but contact transmission of A (H3N2) virus seemed to be efficient at different level of humidity and 30 °C. 5 It remains unclear if high temperature and humidity levels have effect on aerosol and contact transmission of pre-2009 A(H1N1), A(H1N1)pdm09, B/Victoria and B/Yamagata virus among hosts and their stability on surfaces. Of note, an experimental study found the survival durations of A(H3N2) strains on Swiss banknotes were significantly longer than pre-2009 A(H1N1) and B/Victoria virus. 6 Further studies are needed to understand how efficient are these transmission modes for different influenza subtypes or lineages, which is/are dominant mode(s) of transmission among hosts, and which of potential mechanisms is at play under humid and hot condition.
One of our findings was the mutual inverse association between A(H3N2) and A(H1N1)pdm09 epidemics, which provided the evidence on interference between the two influenza A subtypes perhaps possibly due to multiple immune mechanisms. 7 However, our study showed B/Yamagata epidemics were positively correlated with A(H3N2) epidemics, suggesting B/Yamagata epidemics across over 12 study years that were weak could get well along with simultaneous weak H3N2 epidemics.
Understanding of influenza seasonality is important to define optimal timing of influenza vaccination campaigns. Our study indicated that A(H3N2) virus brought about twice-annual epidemics in some years in mid-latitude Chinese provinces and more frequent summertime epidemics in southernmost Chinese provinces, which questions if a single annual influenza vaccination campaign starting in October can offer optimal protection against summertime epidemics of A (H3N2) virus in mid-latitude and southernmost Chinese provinces. In recent years, It has been reported that mismatches of A(H3N2) virus between the influenza vaccine strains and circulating strains were identified frequently, 8 and vaccine effectiveness of A(H3N2) virus declined within 4-6 months postvaccination. 9 In conclusion, we identified the heterogeneity of seasonality pattern of pre-2009 A(H1N1) or A(H3N2) virus in three epidemiological regions of China, and different environment predictors for influenza subtypes and lineages in the southernmost provinces. Further work should focus on understanding difference in virus survival, transmission by influenza subtype and lineage under humid and hot conditions. 
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Out of the ten patients with imported CHIKV infection examined in this study, nine patients had traveled back from Myanmar and one patient had travelled back from Thailand ( Fig. 1 (A) ). All the patients displayed different degrees of symptoms, such as fever, cough, muscle pain, and rash. The details of all the symptoms are shown in Table 1 . CHIKV infection was diagnosed using specific real-time reverse transcription-PCR. Serum specimens were collected from the ten patients that tested positive for CHIKV by real-time PCR analysis, in Yunnan between May 7, 2019 and August 1, 2019. The current study was approved by the Medical Ethics Committee of Kunming University of Science and Technology. Written informed consent was obtained from all the participants.
